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Abstract
Although many studies have analyzed HLA allele frequencies in several ethnic groups in patients with scleroderma (SSc),
none has been done in French Caucasian patients and none has evaluated which one of the common amino acid
sequences,
67FLEDR
71, shared by HLA-DRB susceptibility alleles, or
71TRAELDT
77, shared by HLA-DQB1 susceptibility alleles in
SSc, was the most important to develop the disease. HLA-DRB and DQB typing was performed for a total of 468 healthy
controls and 282 patients with SSc allowing FLEDR and TRAELDT analyses. Results were stratified according to patient’s
clinical subtypes and autoantibody status. Moreover, standardized HLA-DRß1 and DRß5 reverse transcriptase Taqman PCR
assays were developed to quantify ß1 and ß5 mRNA in 20 subjects with HLA-DRB1*15 and/or DRB1*11 haplotypes. FLEDR
motif is highly associated with diffuse SSc (x
2=28.4, p,1026) and with anti-topoisomerase antibody (ATA) production
(x
2=43.9, p,1029) whereas TRAELDT association is weaker in both subgroups (x
2=7.2, p=0.027 and x
2=14.6, p=0.0007
respectively). Moreover, FLEDR motif- association among patients with diffuse SSc remains significant only in ATA subgroup.
The risk to develop ATA positive SSc is higher with double dose FLEDR than single dose with respectively, adjusted
standardised residuals of 5.1 and 2.6. The increase in FLEDR motif is mostly due to the higher frequency of HLA-DRB1*11
and DRB1*15 haplotypes. Furthermore, FLEDR is always carried by the most abundantly expressed ß chain: ß1 in HLA
DRB1*11 haplotypes and ß5 in HLA-DRB1*15 haplotypes. In French Caucasian patients with SSc, FLEDR is the main
presenting motif influencing ATA production in dcSSc. These results open a new field of potential therapeutic applications
to interact with the FLEDR peptide binding groove and prevent ATA production, a hallmark of severity in SSc.
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Introduction
Systemic Sclerosis (SSc) or Scleroderma, is a chronic autoim-
mune disease with unknown aetiology, characterized by fibrosis,
vascular alterations and autoantibodies. Scleroderma is stratified
by clinical criteria into two subtypes: limited cutaneous SSc (lcSSc)
mainly affecting the hands, arms and face, and diffuse cutaneous
scleroderma (dcSSc), affecting a large area of the skin, at increased
risk of cardiac disease, interstitial lung disease, renal crisis and
early death. Specific autoantibodies correlate with subtypes. Anti-
centromere antibodies (ACA) and anti-topoisomerase antibodies
(ATA) are respectively a hallmark of lcSSc and dcSSc, although
not always detected and sometimes observed in each other group.
Other autoantibodies, such as anti-RNA polymerase, antifibrilllin
(AFA) or anti-U3RNP associate with particular clinical manifes-
tations [1,2,3,4].
Disease subtypes and auto-antibody profiles are strongly
associated with HLA-DRB and DQB alleles. The most frequently
reported associations with dcSSc are HLA-DRB1*11, HLA-
DQB1*03 among European and North American Caucasians
and Africans [3,5,6]. However autoantibody specificities are
different depending upon the HLA-DRB1*11 allele: HLA-
DRB1*11:04 is associated with ATA in Caucasians and HLA-
DRB1*1101 with AFA in Africans. HLA-DRB1*15:02- HLA-
DQB1*06:01 haplotypes are commonly found among Asians with
dcSSc and ATA [7]. Less commonly mentioned are associations of
HLA-DRB1*0802 with dcSSc in Japanese and HLA-DRB1*0804
with ATA positive patients in American blacks [3,7,8].
Most common HLA-DR associated with dcSSc (HLA-DRB1*
11:01, *11:04, *15:01, *08:02…) have in common an amino acid
sequence
67FLEDR
71 on their ß chain (Table 1). Similarly, most
common HLA-DQB1 susceptibility alleles, DQB1*03:01, *03:02,
*04:01, *04:02, *06:01 and *06:02, code for a common
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77 motif on their ß chain (Table 2). Reveille et al.
have proposed that additionally to TRAELDT, an amino acid,
tyrosine at position 30 (
30Y) present on HLA-DQB1*03 and
DQB1*06:01-:03 and *6:05-:07 alleles (see Table 2) strengthens
the association of ATA with Caucasians and African Americans
[9].
HLA-DR molecules are heterodimers composed of a non-
polymorphic a chain, encoded by DRA and a highly polymorphic
ß chain (ß1 to ß5) encoded by DRB1*, DRB3*, DRB4* or DRB5*
genes. In HLA-DR15 molecules, the a chain associates either with
a ß1 or ß5 chain coded respectively by DRB1*15 or DRB5*01.
The
67FLEDR
71 motif is only expressed on the ß5 chain.
Conversely, in HLA-DR11 molecules, the
67FLEDR
71 motif is
expressed on the ß1 chain encoded by DRB1*11 and not on the
co-expressed ß3chain encoded by DRB3*02. Consequently, two
heterodimeric HLA-DR molecules are co- expressed at the cell
surface. For HLA-DR15, a chain associates with ß1 or ß5 and for
DR11, a chain associates with ß1 or ß3. But often only
heterodimers with ß1 chains are taken into consideration for
antigen presentation purpose, as other chains are often considered
as accessory chains. If indeed protein expression for ß1 chains is
higher, a person carrying the FLEDR shared epitope on the HLA-
DR15 haplotype would have less expression and a deficient
FLEDR restricted antigen presentation compared to a person
carrying it on the HLA-DR11 haplotype.
In the current study, we evaluated for the first time the relative
risk conferred by one or two
67FLEDR
71 and/or one or two
71TRAELDT
77 motives among our Caucasian French patients
with SSc. As we know, from previous studies, classification by
clinical subtypes and autoantibody profiles could influence results,
we conducted a complete analysis with both classifications to
determine whether FLEDR and/or TRAELDT motives influence
susceptibility to the limited or diffuse form of SSc and/or to
autoantibody subsets. We further evaluated the importance of the
ß chain carrying the FLEDR shared epitope by quantifying levels
of ß chain transcripts.
Methods
Patients and Controls
We included 282 Caucasian patients with SSc with no
overlapping disease, all with defined SSc type (94 diffuse SSc;
188 limited SSc) and auto-antibody status known for 243 of them
(80 without ATA or ACA, 89 with ACA and 74 with ATA).
Patients were enrolled in collaboration with 7 French hospitals
from Paris, Marseille and Lille and fulfilled the criteria of LeRoy
for SSc [10]. Altogether 235 women and 47 men were analysed for
HLA-DR and DQ allele frequencies. Mean age at diagnosis was
49.3 years +14.3 (mean 6 SD).
In parallel, 468 healthy Caucasian controls were recruited at the
Centre d’Examen de Sante ´ de l’Assurance Maladie (CESAM),
Marseille, France (N=154, mean age at the inclusion was 52.5
years 6 7.5 [mean 6 SD]) and at Claude Huriez Hospital in Lille,
France (N=314, mean age at inclusion was 35.4 years 6 10.2
[mean 6 SD]). None of the controls had any symptom or familial
history of autoimmune disorder.
Ethics Statements
Controls from Marseille are registered at INSERM under the
Biomedical Research Protocol number RBM-04-10.
Controls from Lille were drawn from a DNA bank created in
the biological laboratory in 1993. Written consent forms obtained
according to the Declaration of Helsinki were signed [11].
HLA-DRB1 and DQB1 Typing
Genomic DNA was extracted from peripheral blood by
standard methods and HLA genotyping was performed either by
using PCR-RFLP, as previously described for samples received in
Lille or sequence-specific oligonucleotide (SSO) HLA-DRB1 and
HLA-DQB1 typing kit, (RELI SSO, Dynal, Invitrogen, Brombor-
ough, Wirral, UK) according to manufacturer’s protocol as
previously described for samples received in Marseille [12,13].
Allelic typing for DRB1 was done at Etablissement Franc ¸ais du
Sang (EFS, Marseille, France) for samples received in Marseille.
RNA Preparation and cDNA Synthesis
Total RNA was extracted from PBMC using GenElute
Mammalian total RNA Miniprep Kit (Sigma-Aldrich, St Louis
MO, USA). For each RNA sample, DNase I digestion was
included as recommended (Sigma-Aldrich, St Louis MO, USA).
Table 1. Shared amino acid sequences of the most common
DRß chains.
DRB1 alleles Amino acid number
67 68 69 70 71
*01:01, *01:02, *04:03–08, *14:02 L L E Q R
*01:03, *04:02, *11:02, *13:01, *13:02, *13:04 I – – D E
*15:01-:03 I –––A
* 1 5 : 0 4 F–––A
*16:01, *16:03, *16:04, *16:08 F ––D –
* 1 6 : 0 2 , * 1 4 : 0 3 –––D–
*16:05, *16:07, *12:01, *12:03–05, *07:01,
*0703, 0803
I ––D–
* 0 3 : 0 1 – 0 3 : 1 1 , * 0 4 : 0 1 ––––K
*11:01, *11:04–06, *11:09 F ––D –
*11:03 F – – D E
* 1 1 : 0 7 ––––K
*12:02, *13:05 F ––D –
*13:03 I – – D K
* 1 4 : 0 1 , * 1 4 : 0 4 –––R–
*08:01, *08:02, *08:04–09 F ––D –
*09:01 F – – R –
* 1 0 : 0 1 –––R–
DRB3 alleles
*01:01–03, *02:01–08, *03:01–03 ––––K
DRB4 alleles
*01:01-:05 –––R–
DRB5 alleles
*01:01,*01:02,*01:04,*01:05 F ––D –
* 0 1 : 0 3 –––DT
* 0 1 : 0 6 , * 0 2 : 0 2 , * 0 2 : 0 3 I –––A
*01:07 I – – D –
*01:09 F – – N –
* 0 2 : 0 4 F–––A
doi:10.1371/journal.pone.0036870.t001
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quality was ascertained with Agilent Analyser (Agilent RNA 6000
Nano Kit, Agilent Technologies, Germany). Total RNA was
reverse-transcribed using Enhanced Avian HS RT-PCR kit
(Sigma-Aldrich, St Louis MO, USA) according to manufacturer’s
recommendations.
Quantitative Comparison of mRNA from HLA-DRB1*15/
HLA-DRB5*01 and HLA-DRB1*11/HLA-DRB3*02
For HLA-DRB1*15/DRB5*01 assays, we used previously
described real-time PCR assay from Prat et al. with some
modifications in primers sequences [14]. For HLA-DRB1*15
assay, the forward primer was modified: 59-
GCTCCCCACTGGCTTTGT-39, a new reverse primer and
probe were designed: 59-GGCTGTTCCAGTACTCAGCG-39
and 59FAM- ACCACGTTTCCTGTGGCAGCCTAAGAG-
TAMRA39, respectively. For HLA-DRB5*01 assays, only the
forward primer was modified: 59- TGGAGGTTCCTACATGG-
CAA-39.
We designed HLA-DRB1*11 and HLA-DRB3*02 assays. To
ensure that genomic DNA was not amplified, forward primers for
each assay were designed to span Exon 1-Exon 2 borders. HLA-
DRB1*11 forward primer, reverse primer and probe had
respectively the following sequences: 59-GGACACCAGAC-
CACGTTTCT-39,5 9-CGCACGTACTCCTCTTGGTTATA-
39 and 59FAM-ATTGAAGAAATGACACTCAGACGTAGAG-
TACTCC-TAMRA39. HLA-DRB3*02 primers and probe design
was as follow: forward primer 59-GGACACCCGACCACGT-39,
reverse primer 59-CGCGTACTCCTCCTGGTTAT-39 and
probe 59FAM-CTTGGAGCTGCTTAAGTCTGAGTGT-
CATTTC-TAMRA39.
As quantitative comparisons between mRNAs are not trustable
since no perfect gene reference exist, we cloned PCR products
from each assay (DRB1*15, DRB5*01, DRB1*11 or DRB3*02) in
pCR4-TOPO plasmids (pCR4-TOPO TA Cloning Kit, Invitro-
gen, Carlsbad, CA) to calibrate standards curves from these
constructions, as explained below. After bacterial transformation
and plasmid extraction (QIAprep Spin Miniprep kit, Qiagen),
each construct was checked by sequencing (Cogenics, Grenoble
France). Plasmids were then linearized with NcoI restriction
enzyme (Invitrogen, Carlsbad, CA) and concentrations for the 4
constructs were adjusted by using a common set of primers and
probe specific to the plasmid sequence and designed as follows :
forward primer 59-CAGAATTAACCCTCACTAAAGGGACT-
39, reverse primer: 59-ATAGGGCGAATTGAATTTAGCG-39
and probe 59FAM-TCCTGCAGGTTTAAACGAATTCGCC-
TAMRA39. The 4 standards were then serially diluted. Normal-
ization of concentrations between the 4 constructs was possible
because inserts were very similar in size (210 bp and 193 bp for
HLA-DRB1*15 and –DRB5*01 respectively and 114 bp and
111 bp for HLA-DRB1*11 and –DRB3*02 respectively). Stan-
dards were run with their own set of primers and probes.
Adjustment for PCR efficiency of each curve was done and
relative comparison between quantities of HLA-DRB1*15/
DRB5*01 mRNA and HLA-DRB1*11/DRB3*02 mRNA was
calculated.
Statistical Analysis
Pearson chi-square tests with the adjusted standardized residual
method [15] were used to compare frequencies and give an
indication of the strength of the association for each shared epitope
(FLEDR and TRAELDT) between different groups. Indeed the
x2 test indicates whether there is an association between two
categorical variables. However, it does not in itself give an
indication of the strength of the association. In order to identify the
cells (one dose, two doses…) that have the larger differences
between the observed and expected frequencies, we used the
adjusted standardized residuals. These differences are referred to
as residuals, and they can be standardized and adjusted to follow a
Normal distribution with mean 0 and standard deviation 1 [2].
The adjusted standardized residuals, dij, are given by:
dij~
Oij{Eij ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Eij 1{
ni
N
  
1{
nj
N
   s .
Where Oij is the observed frequency in the cell in row i and
column j and Eij is the expected frequency in the cell in row i and
column j, where ni is the total frequency for row i, nj is the total
frequency for column j, and N is the overall total frequency. The
larger the absolute value of the residual, the larger the difference
between the observed and expected frequencies, therefore the
more significant the association between the two variables.
Adjusted standardized residual .1.96 indicates that the number
of cases in that cell is significantly larger than would be expected if
the null hypothesis were true, with a significance level of 0.05. An
adjusted residual ,2 2.0 indicates that the number of cases in that
cell is significantly smaller than would be expected if the null
hypothesis were true.
Results
FLEDR Motif is Highly Associated with dcSSc (Table 3)
HLA-DRB1 allelic typing was performed on 468 controls and
282 patients with SSc (94 patients with dcSSc and 188 patients
with lcSSc) to identify the FLEDR motif coded by some HLA-
Table 2. Shared amino acid sequences of the most common HLA-DQß chains.
Amino acid number
DQB1 alleles 30 … 71 72 73 74 75 76 77
*05:01, *05:02, *05:03 H … A R A S V D R
*05:04 Y … D–––––
*03:01-*03:04,*06:01/2/5/7/9 Y … T ––EL– T
*06:03, 06:04 H … T ––EL– T
*02:01 S … K – – A – – –
*03:05 Y … T ––EL– T
*04:01, *04:02 Y … D–––––T
doi:10.1371/journal.pone.0036870.t002
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allelic typing was performed on the same number of controls and
patients to identify the TRAELDT motif coded by some HLA-
DQB1 alleles and the amino acid present at position 30 (Table 2
and Table S2). The presence of FLEDR or TRAELDT on one
haplotype is noted: 1 dose, on both haplotypes: 2 doses and on
none: 0 dose.
When patients are divided by clinical subtypes (Table 3),
standardized adjusted residuals give an indication of association
for each motif, as explained above. Presence of 2 doses of FLEDR
is the most significant risk to develop dcSSc compared to a single
dose (respective adjusted standardized residuals: 3.7 and 2.3, see
Methods). For TRAELDT having 2 doses is also the most
significant risk to develop dcSSc compared to a single dose
(respective adjusted standardized residuals: 2.9 and 21.4).
However if we compare which one of the two motives is
associated with the highest risk to develop dcSSc, FLEDR motif is
at higher risk than TRAELDT (respectively x
2=28.4, p,10
26
and x
2=7.2, p=0.027).
The increase of FLEDR motif in patients with dcSSc is mostly
due to the higher frequency of HLA-DRB1*11 and DRB1*15
alleles (Table S1).
Although TRAELDT motif is increased among patients with
dcSSc, none of the TRAELDT positive alleles (HLA-DQB1*03
and *06) are statistically increased (Table S2).
As it had been previously proposed that tyrosine at position 30
(
30Y) could strengthen the TRAELDT association, we analysed
this possibility. Indeed, the
30Y residue added to TRAELDT
slightly strengthens the TRAELDT association with dcSSc
(x
2=10.5, p=0.0015, data not shown) but remains weaker than
FLEDR association (x
2=28.4, p,10
26).
FLEDR Motif is Highly Associated with Patients with ATA
Patients were divided in three subgroups according to their
autoantibody status (Table 4, Tables S3 and S4): patients
without ACA or ATA (Abneg); patients with ACA (ACApos);
patients with ATA (ATApos).
FLEDR motif is highly associated with ATA positive patients
(x
2=43.9, p,10
29) whereas TRAELDT has a weaker association
(x
2=14.6, p,10
23, Table 4).
Double dose of FLEDR motif is significantly increased among
patients with ATA (28.4%) compared with healthy controls
(9.0%). The risk to develop ATA positive SSc is higher when
double dose FLEDR is present (adjusted standardized residuals:
5.1) than when only one dose is present (adjusted standardised
residuals: 2.6). The increase of FLEDR motif in patients with ATA
is, like for patients with dcSSc, mostly due to the higher frequency
of HLA-DRB1*11 and DRB1*15 alleles (Table S3). The risk to
develop ATA positive SSc is higher when double dose TRAELDT
is present (adjusted standardized residuals: 3.6) than when only
one dose is present (adjusted standardised residuals: 21.2). The
increase of TRAELDT motif in patients with ATA is mostly due
to the higher frequency of HLA-DQB1*03 alleles (Supplemen-
tary Table S4).
Again, the
30Y residue added to TRAELDT slightly strengthens
the TRAELDT association with ATA positive SSc (x
2=19.7,
p=0.00005, data not shown) without being higher than FLEDR
association (x
2=43.9, p,10
29).
Prevalence of FLEDR in ATA Positive dcSSc and Not ATA
Negative dcSSc
Although ATA is a hallmark of dcSSc, not all patients with
dcSSc have ATA, we wondered whether the FLEDR association
was mostly with the clinical subtype (dcSSc ATA+ or 2) or the
autoantibody profile (Table 5). Among the 94 patients with dcSSc
we were able to obtain information for autoantibody status for 85
who divided into 52 ATA positive and 33 ATA negative. When
both groups (dcSSc ATA pos and dcSSc ATA neg) are compared
to healthy controls, the only remaining association is with the
group positive for ATA. Again FLEDR is the most prevalent
shared epitope in this group (x
2=35.2, p,10
27) compared with
TRAELDT (x
2=9.4, p=0.009). For both motives, having 2 doses
confers the highest risk to develop dcSSc with ATA as they have
the highest standardized adjusted residuals (respectively for
FLEDR and TRAELDT: 4.8 and 2.6).
The
30Y residue added to TRAELDT slightly strengthens the
TRAELDT association with ATA positive dcSSc (x
2=13.4,
p=0.0012, data not shown) without being higher than FLEDR
association (x
2=35.2, p,10
27).
Table 3 Prevalence of FLEDR and TRAELDT in patients with SSc divided by clinical subtypes.
DcSSc LcSSc healthy controls
N=94 N=188 N=468
Motif Doses # % Adj. Std Resd
a # % Adj. Std Resd
a # % Adj. Std Resd
a
FLEDR
b 2 21 22.3 3.7 21 11.2 0.0 42 9.0 22.5
1 50 53.2 2.3 84 44.7 0.7 184 39.3 22.2
0 23 24.5 24.6 83 44.1 20.7 242 51.7 3.8
TRAELDT
c 2 44 46.8 2.9 54 28.7 21.7 155 33.1 20.5
1 42 44.7 21.4 101 53.7 0.7 244 52.1 0.4
0 88 . 5 21.8 33 17.6 1.3 69 14.7 0.1
aadjusted standardized residual .1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true
(represented in bold), with a significance level of.05. An adjusted residual ,2 2.0 indicates that the number of cases in that cell is significantly smaller than would be
expected if the null hypothesis were true (represented in italic).
bwhen comparing different subgroups for FLEDR association: DcSSc/LcSSc/healthy controls: x
2=29.1, p,10
25; LcSSc/healthy controls: not significant; DcSSc/healthy
controls: x
2=28.4, p,10
26.
cwhen comparing different subgroups for TRAELDT association: DcSSc/LcSSc/healthy controls: x
2=10.2, p=0.029; LcSSc/healthy controls: not significant; DcSSc/healthy
controls: x
2=7.2, p=0.027.
doi:10.1371/journal.pone.0036870.t003
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Disequilibrium with FLEDR
DRB1*11 alleles (generally ‘‘FLEDR positive’’ except
DRB1*11:02 and *11:03) are in linkage disequilibrium (LD) with
DQB1*03:01 (TRAELDT positive) and HLA-DRB1*15:01 alleles
(FLEDR positive) in LD with HLA-DQB1*06:02 (TRAELDT
positive). Therefore one could argue that the TRAELDT
association observed is only due to LD with FLEDR.
However TRAELDT alone is statistically associated with dcSSc
and ATA positive individuals as the frequency of individuals
negative for FLEDR (0 dose) but positive (1 or 2 doses) for
TRAELDT is statistically higher in patients with dcSSc (x
2=12.9,
p=0.0003) and in patients with ATA (x
2=19.4, p=0.000013)
compared to controls (Tables S5 and S6). This last result
indicates TRAELDT has its own contribution to disease
susceptibility and autoantibody specificity.
Increased mRNAs of Beta Chains with FLEDR Motif in
Patients and Controls
The HLA-DRB1*1104/DRB1*1501 genotype was present in 7
out of 19 patients with ATA positive dcSSc with double dose
FLEDR but rarely seen in healthy controls with double dose
FLEDR (3/42, 2 tailed Fisher’s test, p,0.007, data not shown).
The FLEDR motif is expressed on the ß1 chain in some HLA-
DR haplotypes (i.e. DR11), and on the ß5 chain on other HLA-
DR haplotypes (i.e. DR15, see Table 1). Ratios of HLA-
DRB5*01 (FLEDR
pos)/HLA-DRB1*15 (FLEDR
neg) mRNA ex-
pression were compared in 14 patients with SSc and 6 healthy
controls (Figure 1). Levels of ß5 mRNA (FLEDR
pos) were
systematically higher than levels of ß1 mRNA with a mean ratio of
5.6. This difference was observed in patients and controls.
As a control of our experiments and validation of our
quantitative comparisons, we checked whether levels of ß1 mRNA
were higher than ß3 mRNA in HLA-DR11 haplotypes as
previously described. Indeed, analyses on 5 subjects (2 patients
Table 4 Prevalence of FLEDR and TRAELDT in patients with SSc divided by antibody status.
SSc Ab neg SSc ACA pos SSc ATA pos Healthy controls
N=80 N=89 N=74 N=468
Motif Doses # % Adj. Std Resd
a# % Adj. Std Resd
a # % Adj. Std Resd
a # % Adj. Std Resd
a
FLEDR
b 2 78 . 8 20.7 8 9.0 20.6 21 28.4 5.1 42 9.0 22.4
1 41 51.3 1.6 37 41.6 20.2 42 56.8 2.6 184 39.3 22.6
0 32 40.0 21.2 44 49.4 0.6 11 14.9 25.7 242 51.7 4.0
TRAELDT
c 2 29 36.3 0.5 18 20.2 22.9 39 52.7 3.6 155 33.1 20.6
1 36 45.0 21.1 50 56.2 1.0 33 44.6 21.2 244 52.1 0.8
0 15 18.8 1.0 21 23.6 2.4 22 . 7 23.1 69 14.7 20.4
aadjusted standardized residual .1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true
(represented in bold), with a significance level of.05. An adjusted residual ,2 2.0 indicates that the number of cases in that cell is significantly smaller than would be
expected if the null hypothesis were true (represented in italic).
bwhen comparing different subgroups for FLEDR association: Ab neg/ACA pos/ATA pos/healthy controls: x
2=48.5, p,10
28; Ab neg/healthy controls: not significant;
ACA pos/healthy controls: x
2=0.17, p=0.9; ATA pos: x
2=43.9, p,10
29.
cwhen comparing different subgroups for TRAELDT association: Ab neg/ACA pos/ATA pos/healthy controls: x
2=27.6, p=0.00013; Ab neg/healthy controls: not
significant; ACA pos: x
2=7.9, p=0.02; ATA pos/healthy controls: x
2=14.6, p=0.0007.
doi:10.1371/journal.pone.0036870.t004
Table 5 Prevalence of FLEDR and TRAELDT in patients with dcSSc divided by antibody status.
DcSSc ATA pos DcSSc ATA neg Healthy controls
N=52 N=33 N=468
Motif Doses # % Adj.Std Resd
a # % Adj.Std Resd
a # % Adj.Std Resd
a
FLEDR 2 16 30.8 4.8 39 . 1 20.4 42 9.0 23.6
1 28 53.8 1.9 18 54.5 1.6 184 39.3 22.5
0 8 15.4 24.9 12 36.4 21.3 242 51.7 4.8
TRAELDT 2 27 51.9 2.6 13 39.4 0.5 155 33.1 22.5
1 23 44.2 21.1 16 48.5 20.3 244 52.1 1.1
0 23 . 8 22.1 4 12.1 20.2 69 14.7 1.9
aadjusted standardized residual .1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true
(represented in bold), with a significance level of.05. An adjusted residual ,2 2.0 indicates that the number of cases in that cell is significantly smaller than would be
expected if the null hypothesis were true (represented in italic).
bwhen comparing different subgroups for FLEDR association: dcSSc ATA pos/dcSSc ATA neg/healthy controls: Fisher’s exact test p,10
26; dcSSc ATA pos/healthy
controls: x
2=35.2, p,10
27; dcSSc ATA neg/healthy controls: not significant.
cwhen comparing different subgroups for TRAELDT association: dcSSc ATA pos/dcSSc ATA neg/healthy controls: Fisher’s exact test p=0.043; dcSSc ATA pos/healthy
controls: x
2=9.4, p=0.009; dcSSc ATA neg/healthy controls: not significant.
doi:10.1371/journal.pone.0036870.t005
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mRNA (FLEDR
pos), with a mean ratio of 4.5, compared to ß3
mRNA (data not shown).
Discussion
The most important genetic factors for scleroderma, as for
many autoimmune diseases, are in the HLA locus. Indeed, results
from worldwide cohorts of patients with SSc, going from early
HLA allele frequency analyses to more recent Genome Wide
Association studies, all show HLA association with SSc. Most
studies have used the classification of diffuse or limited disease,
while others, more recently, have analysed patients subsets
classified according to their autoantibody status. Overall, the
consensus is that HLA-DRB1*11:04 is a risk factor in numerous
Caucasian populations for diffuse SSc and presence of ATA [3,5]
and HLA-DRB1*15:02 and DRB1*0802 in Asian populations [7].
Sequence identity on SSc-associated HLA-DRß chains conducted
to a model of FLEDR shared epitope at amino acid positions 67 to
71 [16]. Similarly, SSc-associated HLA-DQß1 chains have a
common
71TRAELDT
77 sequence, which has been associated
with patients with dcSSc and ATA. Although many studies have
analysed HLA allele frequencies in several ethnic groups including
North American Caucasians, Japanese and Choctaw Indians [2],
no study has evaluated the strength of FLEDR motif compared to
TRAELDT motif. Moreover, to our knowledge, this is the first
study analysing HLA class II shared epitopes in French Caucasian
patients with systemic sclerosis (SSc) stratified by clinical subsets
and autoantibodies. We confirmed two previous findings in
Japanese and Korean patients [16] and showed that FLEDR is
the most prevalent shared epitope for the most severe type of SSc
(dcSSc ATA+) in French Caucasians. We further showed that the
association is linked to autoantibody production rather than
clinical subtype. Finally by using standardized adjusted residual
method we showed that having 2 doses of FLEDR is the higher
risk to develop dcSSc with ATA.
Since TRAELDT association is weaker compared with FLEDR
association, and since TRAELDT is often in linkage disequilib-
rium (LD) with FLEDR, one could think TRAELDT association is
solely due to LD. However we showed that TRAELDT has its
own contribution to disease susceptibility and autoantibody
specificity. A tyrosine at position 30 (
30Y), previously shown to
reinforce the strength of the TRAELDT association with patients
with ATA [9], added significance to the association but still
remained lower than the FLEDR association. Similarly, on the
DRß chain, by a novel approach which consists in subdividing into
biologically relevant smaller sequence features and their variant
types, Karp et al. showed that additional residual amino acids
played a role in the risk to develop SSc [17]. Risk alleles had the
sequence
26F-
28D_
30Y_
37Y_
67F/I_
70D_
71R_
86V. However this
additional effect of residual amino acids on DRß chain was not
as obvious in our cohort as most double dose FLEDR shared
epitopes were HLA-DRB1*11:04/*15:01 and HLA-DRB1*15:01
does carry FLEDR but not the whole risk sequence described
above (ie:
86V).
A parallel can be made between shared epitope in Rheumatoid
Arthritis (RA) and in SSc. In patients with RA, the shared epitope
70QK/RRAA
74 has a strong effect on the risk to develop Anti-
Citrullinated Peptide Antibodies (ACPA) positive RA, whereas this
association, although significant, is weaker in patients without
ACPA [18]. This observation argues the admitted hypothesis that
a particular HLA shared epitope presents particular auto-antigenic
peptides triggering to a T cell helper response, which itself
conducts to a particular auto-antibody production.
The FLEDR motif, by its position in the peptide binding
groove, is determinant for efficient presentation of antigenic
peptides to T cells. Interestingly, we showed that this motif would
be overexpressed when carried by DRß5 chains in HLA-DR15
Figure 1. mRNA expression of DRB5*01 and DRB1*15 in patients with SSc and controls (CTL).
doi:10.1371/journal.pone.0036870.g001
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molecules. Indeed, our results, very similar to Prat et al. recently
found in patients with multiple sclerosis and controls [14], showed
a 5 fold increase of ß5 chain at mRNA level. Prat et al. further
showed that this mRNA increase correlated with a two-fold
increase at protein level. ß5 chains might be then sufficiently
expressed at cell surface to combine with the DRß chain to form
additional DR molecules on the cell surface and be involved in
antigen presentation [14]. These ‘‘accessory chains’’ serve to
extend and complement the peptide repertoire of DRB1 in antigen
presentation [19].
In the current study, not only we confirmed that some HLA-
DRB1 and DQB1 alleles are highly associated with the production
of ATA, but for the first time we statistically evaluated the strength
of each HLA allele common motives. FLEDR is the main
presenting motif involved in ATA production. Knowing better
motives involved in peptide and autoantibody production could
allow developing blocking therapies to prevent ATA production, a
hallmark of higher risk for severe organ involvement, for internal
malignancies and for reduced survival. Indeed, in a recent
publication, by using an in silico molecular docking program to
screen a large ‘‘druglike’’ chemical library, Michels et al. were able
to find small molecules capable of occupying the pockets along the
I-A
g7 binding groove in the NOD mouse model of spontaneous
autoimmune diabetes [20].
The focus of this paper has been the amino-acid sequence from
position 67 to 71 encoded by HLA-DRB and the amino-acid
sequence from position 71 to 77 encoded by HLA-DQB1, but
classification of HLA-DRB1 genotypes according to their risk
should provide diagnostic markers for SSc. Indeed we found that
HLA-DRB1*1104/DRB1*1501 was the most common FLEDR
double dose genotype among patients with ATA and was rarely
seen in healthy controls. This highlights a synergistic effect of
different alleles from each haplotype. Double dose of shared
epitope but also compound heterozygosity, may confer a higher
risk to disease as it has been shown in rheumatoid arthritis, type 1
diabetes, celiac disease and systemic lupus erythematosus suggest-
ing a common autoimmune pathway [19,21,22,23,24].
Future larger studies should also focus on classification by HLA
genotypes at risk for SSc to provide help in clinical practice for a
disease still difficult to diagnose.
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